About INOPASE

INOPASE develops wireless, implantable neuromodulation devices for closed-loop therapy. Their devices provide targeted treatment for conditions like overactive bladder and epilepsy by directly modulating nerve activity.

```xml <problem> Current treatments for chronic neurological diseases like drug-resistant epilepsy and refractory overactive bladder often have limited efficacy, imprecise stimulation, and require frequent invasive surgeries. Existing neuromodulation techniques lack personalized approaches and the ability to detect and prevent symptoms before they occur. </problem> <solution> INOPASE develops wireless, implantable neuromodulation devices that use closed-loop technology to provide personalized treatment for chronic neurological diseases. Their system uses advanced algorithms to detect pre-symptomatic indicators and deliver dynamic stimulation therapy tailored to the individual patient's condition. The devices offer advantages such as minimally invasive implantation, precise stimulation through high-density electrodes, and the potential for complete remission by regenerating neural function. INOPASE's technology aims to address the limitations of current neuromodulation techniques by providing timely, adaptable, and effective treatment. </solution> <features> - Wireless powered implantable device for long-term use - Closed-loop neuromodulation with real-time feedback and automatic adjustment of stimulation parameters - Pre-symptomatic detection algorithms for proactive intervention - Personalized treatment adaptable to individual patient conditions - High-density EEG recordings (64-128 electrodes) for precise identification of the epileptic onset zone - Minimally invasive implantation procedure - Potential for complete regeneration of neural function and symptom-free life </features> <target_audience> The primary target audience includes individuals suffering from drug-resistant epilepsy and refractory overactive bladder, as well as clinicians specializing in neurology and urology seeking advanced neuromodulation solutions. </target_audience> ```

What does INOPASE do?

When was INOPASE founded?

INOPASE was founded in 2021.

Who founded INOPASE?

INOPASE was founded by Ryosuke Kimura.

Ryosuke Kimura - Founder

Founded

2021

Employees

10 employees

Investors

It Farm Lifetime Ventures

INOPASE

Founded 202110200+ followers9/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.

Updated 14 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Current treatments for chronic neurological diseases like drug-resistant epilepsy and refractory overactive bladder often have limited efficacy, imprecise stimulation, and require frequent invasive surgeries. Existing neuromodulation techniques lack personalized approaches and the ability to detect and prevent symptoms before they occur.

Solution

INOPASE develops wireless, implantable neuromodulation devices that use closed-loop technology to provide personalized treatment for chronic neurological diseases. Their system uses advanced algorithms to detect pre-symptomatic indicators and deliver dynamic stimulation therapy tailored to the individual patient's condition. The devices offer advantages such as minimally invasive implantation, precise stimulation through high-density electrodes, and the potential for complete remission by regenerating neural function. INOPASE's technology aims to address the limitations of current neuromodulation techniques by providing timely, adaptable, and effective treatment.

Target Audience

The primary target audience includes individuals suffering from drug-resistant epilepsy and refractory overactive bladder, as well as clinicians specializing in neurology and urology seeking advanced neuromodulation solutions.

Features

Wireless powered implantable device for long-term use
Closed-loop neuromodulation with real-time feedback and automatic adjustment of stimulation parameters
Pre-symptomatic detection algorithms for proactive intervention
Personalized treatment adaptable to individual patient conditions
High-density EEG recordings (64-128 electrodes) for precise identification of the epileptic onset zone
Minimally invasive implantation procedure
Potential for complete regeneration of neural function and symptom-free life